Cloud Therapy freebase e-liquids are manufactured by Vapourium in New Zealand using pharmaceutical-grade ingredients and supplied in 120mL gorilla-style bottles with child-resistant caps. Each variant is available in nicotine concentrations of 0mg/mL, 1mg/mL, 3mg/mL, and 6mg/mL, within the maximum threshold set under New Zealand's regulated product requirements.

The freebase nicotine formulation delivers a lower throat sensation at equivalent concentrations compared to nicotine salt alternatives, making these products compatible with sub-ohm and direct-to-lung style hardware. The base composition uses a vegetable glycerine and propylene glycol blend optimised for vapour production in higher-wattage devices, typically operating between 40W and 100W with coil resistances below 1.0 ohm.

All Cloud Therapy e-liquids are notified products under the Smokefree Environments and Regulated Products Act 2020 and meet New Zealand labelling and packaging standards, including ingredient disclosure and nicotine content warnings. The ingredient base consists of USP-grade vegetable glycerine, USP-grade propylene glycol, food-grade flavour concentrates, and nicotine where applicable sourced to pharmaceutical standards.

The 120mL bottle format utilises a squeezable LDPE plastic container with a fine-tip nozzle for controlled dispensing into refillable tank systems, rebuildable atomisers, and pod devices with refillable cartridges. The child-resistant twist-lock cap complies with current safety packaging regulations.

Storage recommendations include keeping bottles sealed in a cool, dry location away from direct sunlight, with a typical shelf life of twelve to twenty-four months from manufacture when stored correctly. Cloud Therapy products are restricted to persons aged 18 years and over.